Potential for recombinant Babesia bovis antigens to protect against a highly virulent isolate

Parasite Immunology

Volumn 27, Issue 12, 2005, Pages 439-445

  Hope, M ^a   Riding, G ^a   Menzies, M ^a   Colditz, I ^a   Reverter, A ^a   Willadsen, P ^a  

^a CSIRO   (Australia)

Author keywords

Babesia; Recombinant antigen; Vaccine

Indexed keywords

ANTIGEN 11C5; ANTIGEN 12D3; COMPLEMENTARY DNA; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; PROTOZOAL RNA; PROTOZOAL VACCINE; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BABESIA BOVIS; BABESIOSIS; BODY TEMPERATURE; CATTLE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HEMATOCRIT; MONOCYTE; NONHUMAN; PARASITE VIRULENCE; PARASITEMIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BABESIA BOVIS; BABESIOSIS; CATTLE; CATTLE DISEASES; ESCHERICHIA COLI; MONOCYTES; PARASITEMIA; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VIRULENCE;

ANIMALIA; BABESIA; BABESIA BOVIS; BOS TAURUS; ESCHERICHIA COLI;

EID: 27844571846     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2005.00795.x     Document Type: Article

References (24)

1. Perry BO, Randolph TF, McDermott JJ, Sones KR & Thornton PK. Investing in Animal Health Research to Alleviate Poverty. Nairobi, Kenya: ILRI (International Livestock Research Institute); 2002.
2. De Castro JJ. Sustainable tick and tickborne disease control in livestock improvement in developing countries. Vet Parasitol 1997; 71: 77-97.
3. Callow LL, Dalgleish RJ & De Vos AJ. Development of effective living vaccines against bovine babesiosis - the longest field trial? Int J Parasitol 1997; 7: 747-767.
4. Palmer GH & McElwain TF. Molecular basis for vaccine development against anaplasmosis and babesiosis. Vet Parasitol 1995; 57: 233-253.
5. Brown WC & Palmer GH. Designing blood-stage vaccines against Babesia bovis and A bigemina. Parasitol Today 1999; 15: 275-281.
6. Goodger BV, Waltisbuhl DJ, Wright IG & White M. Babesia bovis: analysis of and preliminary vaccination studies with a defined infected erythrocyte membrane binding antigen. Int J Parasitol 1992; 22: 533-535.
7. Wright IG, Casu R, Comins MA et al. The development of a recombinant Babesia vaccine. Vet Parasitol 1992; 44: 3-13.
8. Harper GS, Riddles PW, Waltisbuhl DJ & Wright IG. Applications of recombinant DNA technologies in the development of a vaccine: examples in the development of a vaccine against Babesia. In Vaccines in Agriculture: Immunological Applications to Animal Health and Production, eds Wood PR, Willadsen P, Vercoe JE, Hoskinson RM, Demeyer D. Australia: CSIRO; 1994: 161-169.
9. Gale KG, Waltisbuhl DJ, Wright IG & Goodger BV. Polypeptides, antigens or vaccines protective against babesiosis. US Patent No. 5273884.
10. Bock RE, de Vos AJ, Kingston TG & McLellan DJ. Effect of breed of cattle on innate resistance to infection with Babesia bovis, Babesia bigemina and Anaplasma marginale. Aust Vet J 1997; 75: 337-340.
11. Bock RE, de Vos AJ, Kingston TG, Shiels IA & Dalgliesh RJ. Investigations of breakdowns in protection provided by living Babesia bovis vaccine. Vet Parasitol 1992; 43: 45-56.
12. Sambrook J, Frisch EF & Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, 1989.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
14. Rabilloud T, Carpentier G & Tarroux P. Improvement and simplification of low-background silver staining of proteins by using sodium dithionite. Electrophoresis 1988; 9: 291-299.
15. Edgar JA, Payne AL & Than KA. Phomopsin-macromolecule carrier conjugates - used in vaccines to protect against lupinosis and to produce antibody to de-isolate phomopsin mycotoxins. Australian Patents No. AU9064916-A and AU643464-B.
16. Bock RE, de Vos AJ, Lew A, Kingston TG & Fraser IR. Studies on failure of T strain live Babesia bovis vaccine. Aust Vet J 1995; 72: 296-300.
17. Anderson BH, Watson DL & Colditz IG. The effect of dexamethasone on some immunological parameters in cattle. Vet Res Commun 1999; 23: 399-413.
18. Hope M, Riding G, Menzies M & Willadsen P. A novel antigen from Anaplasma marginale: characterisation, expression and preliminary evaluation of the recombinant protein. Vaccine 2004; 22: 407-415.
19. Bock RE, Kingston TG & de Vos AJ. Effect of breed of cattle on transmission rate and innate resistance to infection with Babesia bovis and Babesia bigemina transmitted by Boophilus microplus. Aust Vet J 1999; 77: 461-464.
20. Goff WL, Johnson WC, Parish SM, Barrington GM, Tuo W & Valdez RA. The age-related immunity in cattle to Babesia bovis infection involves the rapid induction of interleukin 12, interferon-γ and inducible nitric oxide synthase mRNA expression I the spleen. Parasite Immunol 2001; 23: 463-471.
21. Court RA, Jackson LA & Lee RP. Elevated anti-parasitic activity in peripheral blood monocytes and neutrophils of cattle infected with Babesia bovis. Int J Parasitol 2001; 19: 29-37.
22. Schwenk R, Asher LV, Chalom I et al. Opsonisation by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol 2003; 25: 17-25.
23. Ladhani S, Lowe B, Cole AO, Kowuondo K & Newton CRJC. Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. Br J Haematol 2002; 119: 839-847.
24. Chiwakata CB, Hemmer CJ & Dietrich M. High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria. Infect Immun 2000; 68: 394-399.